Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoVOICE trial of neoadjuvant sintilimab + cetuximab + SBRT for locally advanced laryngeal cancer
ChiCTR2500100185Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and cetuximab in laryngeal cancer, sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: 1-year larynx preservation rate, Disease-free survival rate at 1 year and 1 more. Started Apr 2025; status: recruiting.
02
Drugs
sintilimabcetuximab
03
Conditions
laryngeal cancer
Beyond the preview
Go deeper on ChiCTR2500100185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100185.